Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOPAD study of SanaCutan Basiscreme for prevention of atopic dermatitis in high-risk infants
2018-004762-33Phase 3Active
- Sponsor
- InfectoPharm
- Start
- Jul 2019
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SanaCutan Basiscreme in atopic dermatitis (AD) (2 arms), sponsored by InfectoPharm. Primary endpoint: Cumulative incidence of atopic dermatitis at 6 months. Started Jul 2019; status: active.
02
Drugs
SanaCutan Basiscreme
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-004762-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004762-33.